The COMMD1 antibody is a crucial tool for studying the multifaceted roles of the COMMD1 (COpper Metabolism MURR1 Domain containing 1) protein, which is implicated in diverse cellular processes. COMMD1. a member of the COMMD protein family, participates in copper homeostasis, ion transport, NF-κB signaling regulation, and ubiquitination processes. Dysregulation of COMMD1 is linked to pathologies such as Wilson’s disease (due to copper overload), cancer, and inflammatory disorders. Researchers employ COMMD1 antibodies primarily in techniques like Western blotting, immunofluorescence, and immunoprecipitation to assess protein expression, subcellular localization, and interactions with partners like ATP7B or the Cullin-RING E3 ubiquitin ligase complex. Polyclonal antibodies offer broad epitope recognition, while monoclonal variants provide high specificity, aiding in distinguishing COMMD1 from homologous family members. Validating antibody specificity via knockout controls or siRNA knockdown is critical due to potential cross-reactivity. COMMD1 antibodies have advanced studies on molecular mechanisms underlying copper toxicity, NF-κB-driven inflammation, and cancer progression, particularly in hepatocellular carcinoma. Their application extends to diagnostic research and therapeutic target exploration, including drug development for copper-related disorders. As COMMD1’s roles in hypoxia response and immune regulation emerge, these antibodies remain vital for unraveling its context-dependent functions in health and disease.